search results for
Your search term has returned 0 results
Foundation Chair and Professor of Respiratory Medicine
Professor Morice is Head of Respiratory Medicine at HYMS, based at the University of Hull. He is also an Honorary Consultant Physician at Hull & East Yorkshire Hospitals NHS Trust. Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.
The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.
Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.
Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening
Jahanfar, F., Sadofsky, L., Morice, A., & D’Amico, M. (2022). Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening. Membranes, 12(10), Article 954. https://doi.org/10.3390/membranes12100954
Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985
ATP, an attractive target for the treatment of refractory chronic cough
Zhang, M., Sykes, D. L., Sadofsky, L. R., & Morice, A. H. (2022). ATP, an attractive target for the treatment of refractory chronic cough. Purinergic Signalling, 18, 289-305. https://doi.org/10.1007/s11302-022-09877-z
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
Cotton, S., Devereux, G., Abbas, H., Briggs, A., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23(1), Article 307. https://doi.org/10.1186/s13063-022-06226-8
Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?
Morice, A. H. (2022). Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?. American Journal of Respiratory and Critical Care Medicine, 205(9), 985-986. https://doi.org/10.1164/rccm.202201-0083ED
Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.
Project
Funder
Grant
Started
Status
Bayer Pharma AG
£61,101.00
18 July 2018
Complete
Hull University Teaching Hospitals NHS Trust
£21,285.00
1 June 2016
NIHR National Institute for Health Research
£27,108.00
1 June 2017
£42,493.00
1 August 2017
£19,047.00
18 May 2014
AstraZeneca UK Limited
£163,413.00
1 October 2016
Aradigm Corporation
£30,144.00
31 October 2014
Aerocrine AB
£30,000.00
2 November 2015
Afferent Pharmaceuticals Inc
£62,207.00
5 October 2015
£140,667.00
£22,020.00
1 March 2016
Sanofi Aventis
£27,342.00
1 October 2017
£22,286.00
1 June 2020
£16,546.00
1 December 2017
£26,613.00
1 January 2021
Centre for Clinical Sciences
Browser does not support script.